At 6.9% CAGR, the South & Central America Benign Prostatic Hyperplasic Devices Market is projected to be worth US$ 218.16 million by 2028, says Business Market Insights   

According to Business Market Insights’ research, the South & Central America benign prostatic hyperplasic devices market was valued at US$ 146.38 million in 2022 and is expected to reach US$ 218.16 million by 2028, registering an annual growth rate of 6.1% from 2022 to 2028. Growing product approvals and launches and boosting prevalence of BPH among men along with increasing.               

Leading players in the benign prostatic hyperplasic devices market focus on expanding their customer reach across emerging markets by expanding their distribution networks and augmenting manufacturing capabilities. In addition, high investments in life science and healthcare research in emerging countries play a crucial role in the upgrading of the latest technologies in developing countries. In turn, this supports the inclination toward advanced benign prostatic hyperplasia treatments. Crucial benign prostatic hyperplasic device manufacturers in Brazil are expected to witness lucrative opportunities in the future owing to the large patient pool and high benign prostatic hyperplasia prevalence, increasing disposable income, improving healthcare infrastructure, and growing medical tourism in countries across the region.

On the contrary, lesser awareness about prostate health among men. 

• Based on product, the South & Central America benign prostatic hyperplasic devices market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment held 34.8% market share in 2022, amassing US$ 50.94 million. It is projected to garner US$ 75.13 million by 2028 to expand at 6.7% CAGR during 2022–2028.
• Based on procedure type, the South & Central America benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held 28.4% market share in 2022, amassing US$ 41.53 million. It is projected to garner US$ 63.95 million by 2028 to expand at 7.5% CAGR during 2022–2028.
• Based on end user, the South & Central America benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held 41.9% market share in 2022, amassing US$ 61.38 million. It is projected to garner US$ 90.58 million by 2028 to expand at 6.7% CAGR during 2022–2028
• Based on country, the South & Central America benign prostatic hyperplasic devices market has been segmented into Brazil, Argentina, and Rest of SAM.  Our regional analysis states that Brazil captured 58.8% market share in 2022. It was assessed at US$ 86.05 million in 2022 and is likely to hit US$ 131.15 million by 2028, exhibiting a CAGR of 7.3% during the forecast period.  

Key players dominating the South & Central America benign prostatic hyperplasic devices market are KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; and Richard Wolf GmbH among others.

• In June 2021, Olympus Corporation acquired Israeli medical device company Medi-Tate Ltd. Through this acquisition, Olympus expanded its business line in offering in-office treatment for benign prostatic hyperplasia (BPH) treatment and solidified its position as a leader in the field of urological devices.
• In September 2021, Olympus was selected to exhibit the iTind device, a temporarily implanted device for the relief of enlarged prostate symptoms, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange virtually from September 21-23.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com